Backed by £7 million in equity funding, the company has created ten new jobs, secured its first UK healthcare services contracts, distribution agreements in the USA, and generated £65,000 in revenue by Q2 2025.

Eventum Orthopaedics specialises in surgical implant alignment technology, enhancing outcomes in knee and hip replacement surgeries. With one in five knee replacement patients dissatisfied with their outcomes, the company’s flagship product, Quadsense, addresses this gap by improving accuracy and reducing post-operative complications. Early adoption in New Zealand, and growing interest from UK and international surgeons, have positioned Eventum as a key player in medical device innovation.

To build on this momentum, the company is developing Hipsense, a next-generation device designed to enhance hip replacement surgery by enabling more precise implant positioning. This innovation, backed by grant funding and strategic support, is expected to improve patient outcomes and reduce revision surgeries, saving healthcare systems, such as the NHS, significant costs.
John Naybour, CEO of Eventum Orthopaedics, says: “Our mission is to bring precision and confidence to orthopaedic surgery. By equipping surgeons with cutting-edge tools, we are improving patient outcomes, reducing complications and helping healthcare providers enhance efficiency.”

Funding growth and scaling operations

Since 2021, Innovate UK Business Growth has worked closely with Eventum Orthopaedics. Innovation and Growth Specialist, Marcus Orton, developed a bespoke action plan in collaboration with the company, focusing on securing grant funding and supporting investment readiness, international expansion and regulatory navigation. This support has helped the company secure critical funding and connect with the health sector, NHS Trust Innovation Agencies, regional authorities, and engage successfully with the UK and international stakeholders.

Through targeted funding support, Eventum secured a £67,000 grant through Innovate UK’s Launchpad programme via the West Yorkshire Combined Authority (WYCA) and the associated HealthTech Cluster. This programme supports the most innovative businesses in advancing their ideas towards commercialisation, contributing to local economic growth. Eventum also received an additional £100,000 WYCA grant, enabling access to research and development (R&D) resources at Leeds University and the expertise needed to further develop its technology.

These resources contributed to the development of Hipsense and strengthened the company’s position in the med-tech sector. The support has primarily focused on grant funding strategy and application support, product and business development and UK and international stakeholder engagement. When the company raised £2.5m in equity investment, allowing it to expand its team from five to eight employees and transition from a start-up to a commercial-scale enterprise. Recently closing a £3.8m round provides resources to address market vital deployment and further product development, securing employment and supply chain resources for the team.

John explains: “Innovate UK Business Growth’s guidance has been crucial in refining our funding applications, helping us navigate the regulatory landscape and positioning us for long-term, sustainable growth. Their insights and connections have accelerated our progress, enabling us to expand into new markets and secure valuable partnerships.”

Expanding internationally with strategic support

With support from Innovate UK Business Growth, Eventum has gained access to the BSOL Standards Online facility, delivered by the British Standards Institute (BSI), and gained ISO 13485 certification, a globally recognised standard for ensuring the quality and safety of medical devices. This has contributed to their successfully navigating complex medical device regulations, achieving the UKCA Mark, and USA 510(k) clearance late in 2024. These key milestones have enabled the launch of Quadsense in the UK and USA, pivotal markets to engage with.

Promising progress is being made in the UK, as the company pursues NHS adoption. Securing NHS Dynamic Purchasing (DPS) recognition and sales with NHS Trusts, including the Royal Surrey NHS Foundation Trust and Royal Devon University Healthcare NHS Trust, is building experience in addressing, compiling, and presenting the business case required for successful NHS deployment that is both beneficial to the UK population, and highly regarded elsewhere.

Looking beyond the UK, Eventum has prioritised international growth, participating in Innovate UK’s Global Explorers programme to prepare for entry into the US market. A recent funded visit, worth just over £7,000, has helped establish key relationships with distributors and medical professionals, building on the foundational groundwork of the FDA regulatory approval, research and development, and commercial activity in North America.

John adds: “Innovate UK Business Growth’s support has been invaluable in helping us access international markets. Their introductions to industry leaders and guidance on regulatory frameworks have positioned us well for expansion into the USA.”

Strengthening future impact through innovation

The support from Innovate UK Business Growth has not only accelerated Eventum’s growth but also contributed to the UK economy and society through job creation, regional investment and improvements in healthcare efficiency and patient outcomes.

John concludes: “Eventum Orthopaedics has grown significantly over the past few years and the support from Innovate UK Business Growth has played a key role in our journey. From securing funding to navigating regulatory and institutional pathways, their expertise and referrals, have helped us overcome key challenges and position ourselves for long-term success.”

As Eventum continues to expand, its pioneering technology is set to enhance surgical outcomes worldwide, reducing complications and improving patient recovery—delivering a lasting impact on the med-tech industry, healthcare resources, and beyond.

Innovate UK Business Growth’s guidance has been crucial in … positioning us for long-term, sustainable growth. Their insights and connections have accelerated our progress, enabling us to expand into new markets and secure valuable partnerships.

– John Naybour, CEO of Eventum Orthopaedics